Navigation Links
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Date:5/18/2009

ied accounts receivable and other liquidity factors, the Company's ability to obtain annual renewals of or replacements for its credit facilities, the effects of a going concern audit opinion on the Company's operations, the Company's ability to successfully transition its billing function in-house from a third party vendor, whether the conditions to payment of all or any portion of the contingent consideration from the Company's prior sale of its instrument systems business to Zeiss are satisfied, the Company's ability to remediate the material weaknesses in the Company's internal control over financial reporting, the continuation of favorable third party payer reimbursement for laboratory tests, the Company's ability to obtain additional financing on acceptable terms or at all, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, the Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The Company does not assume any obligation to update any forward-looking statements or other information contained in this document.

    Contact:
    Matt Clawson
    949.474.4300
    <
'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
3. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Clarient to Commercialize Novel Breast Cancer Profile
9. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4
... 4, 2011 Reportlinker.com announces that a ... its catalogue: Nanotechnology in ... Approaches to Fulfill High Potential ... in Drug Delivery - Technological Improvements and ...
... NEW YORK, Jan. 4, 2011 Reportlinker.com announces ... in its catalogue: Financial Health ... China http://www.reportlinker.com/p0357094/Financial-Health-of-Biotechnology-and-Drugs-Industry-in-India-and-China.html ... of Indian and Chinese biotechnology companies across 2 ...
... BEACH, Calif., Jan. 4, 2011 Genesis Biopharma, Inc. ... company developing targeted cancer therapies, today announced that it ... to which it entered into definitive agreements with accredited ... the Genesis Biopharma common stock for a purchase price ...
Cached Biology Technology:Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential 2Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China 2Genesis Biopharma Raises $845,000 in Private Financings 2
(Date:8/22/2014)... and the bees. But that old expression leaves ... fertilization process for flowering plants is particularly complex ... female reproductive cells. New research from an international ... including Carnegie,s Wolf Frommer, David Ehrhardt, and Guido ... that guides flowering plant fertilization. It is published ...
(Date:8/21/2014)... 21, 2014 Nxt-ID, Inc. (OTCQB: NXTD), a ... market, announced today that its shares of common stock ... issued in its proposed underwritten public offering of common ... The Nasdaq Capital Market, subject to closing of its ... warrants, and will trade under the symbol "NXTD" and ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan ... has agreed to a partnership with Gabriel Health ... fastest growing Certified Nursing Assistant preparatory ... Institute  an exclusive member of Binary,s LiveScan service ... Biometrics will improve its service capabilities by ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... invasive species move into new areas, they often lose their ... new research from evolutionary biologists at the University of South ... help house sparrows, one of the world,s most common bird ... in Proceedings of the Royal Society B , Biological ...
... FAHA, Director of the Cardiovascular Research Center (CVRC) at ... heart for nearly three and a half decades. Over ... research, work that led to his recent recognition with ... the Basic Cardiovascular Science (BCVS) Council Distinguished Achievement ...
... relatives of papaya were certain trees from the Andes, the ... species of the papaya family instead revealed that the closest ... tree with stinging hairs occurring from Mexico to Guatemala and ... from cloud forests in the Sierra de Juarez in Oaxaca, ...
Cached Biology News:USF researchers show invasive sparrows immune cells sharpen as they spread 2Temple's Dr. Steven Houser recognized by the American Heart Association 2Temple's Dr. Steven Houser recognized by the American Heart Association 3
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)...
... terminators, template DNA, primers, salts or other ... have proved critical for both standard and ... work with dye terminator cycle sequencing chemistries ... unique uniformity of the magnetic paeticles guarantees ...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
X-gal,1g...
Biology Products: